XML 37 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1

Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)		1 Months Ended			3 Months Ended		9 Months Ended		12 Months Ended
	May 10, 2017 USD ($)	Jan. 31, 2014 USD ($) Program	Jun. 30, 2012 Targets	Jan. 31, 2012 USD ($) Targets	Sep. 30, 2017 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($) Product	Sep. 30, 2016 USD ($)	Dec. 31, 2014 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Number of research programs | Program		2
Research and development					$ 18,425,000	$ 17,008,000	$ 46,351,000	$ 51,728,000
Pfizer [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues under agreement	$ 70,000,000
Potential amount eligible to receive for certain milestones	208,500,000
Milestone revenue receivable	475,000,000
Milestone payments received							$ 0
Number of products approved | Product							0
Royalty revenues							$ 0
Research program to develop laboratory research reagents							32 months
Deferred revenue					59,600,000		$ 59,600,000
Recognition of upfront fee					6,600,000		10,400,000
Bioverativ Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues under agreement		$ 20,000,000
Potential amount eligible to receive for certain milestones		115,800,000
Potential amount to be funded for achievement of specified commercialized and sales milestones		160,500,000
Milestone payments received							$ 0
Number of products approved | Product							0
Royalty revenues							$ 0
Research program to develop laboratory research reagents							44 months
Deferred revenue					5,000,000		$ 5,000,000
Recognition of upfront fee					442,000	607,000	1,326,000	1,823,000
Bioverativ Inc [Member] | Sickle cell disease [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone revenue receivable		7,500,000
Bioverativ Inc [Member] | Beta-thalassemia Project [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone revenue receivable		$ 6,000,000
Research and development					2,800,000	1,200,000	7,300,000	5,300,000
Shire AG [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues under agreement				$ 13,000,000
Deferred revenue					1,200,000		1,200,000
Recognition of upfront fee					1,166,000	542,000	2,333,000	1,625,000
Research and development					$ 0	$ 200,000	$ 0	$ 900,000
Number of initial gene targets | Targets				4
Number of gene targets | Targets			5
Recognition of milestone									$ 1,000,000
SB-525 [Member] | Pfizer [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Potential amount to be funded for achievement of specified commercialized and sales milestones	266,500,000
Maximum [Member] | Shire AG [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Aggregate number of gene targets | Targets				7
Maximum [Member] | SB-525 [Member] | Pfizer [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone revenue receivable	300,000,000
Maximum [Member] | Other Products [Member] | Pfizer [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone revenue receivable	$ 175,000,000

X

- Definition

Aggregate additional revenue recognition milestone method revenue achieved.

+ References

No definition available.

+ Details

Name:	sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved
Namespace Prefix:	sgmo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Aggregate additional revenue recognition milestone method revenue eligible to receive.

+ References

No definition available.

+ Details

Name:	sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive
Namespace Prefix:	sgmo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Aggregate number of gene targets.

+ References

No definition available.

+ Details

Name:	sgmo_AggregateNumberOfGeneTargets
Namespace Prefix:	sgmo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Collaboration and license agreements number of products approved under agreement.

+ References

No definition available.

+ Details

Name:	sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
Namespace Prefix:	sgmo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Initial research term of agreement.

+ References

No definition available.

+ Details

Name:	sgmo_InitialResearchTermOfAgreement
Namespace Prefix:	sgmo_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Milestone payments received.

+ References

No definition available.

+ Details

Name:	sgmo_MilestonePaymentsReceived
Namespace Prefix:	sgmo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Milestone​ revenue receivable.

+ References

No definition available.

+ Details

Name:	sgmo_MilestoneRevenueReceivable
Namespace Prefix:	sgmo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Number of gene targets.

+ References

No definition available.

+ Details

Name:	sgmo_NumberOfGeneTargets
Namespace Prefix:	sgmo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of initial gene targets.

+ References

No definition available.

+ Details

Name:	sgmo_NumberOfInitialGeneTargets
Namespace Prefix:	sgmo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Number of research program.

+ References

No definition available.

+ Details

Name:	sgmo_NumberOfResearchProgram
Namespace Prefix:	sgmo_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(d),(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_LicenseAndServicesRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 28
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_RoyaltyRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	us-gaap_CounterpartyNameAxis=sgmo_PfizerMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=sgmo_BioverativIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_SickleCellDiseaseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=sgmo_BetaThalassemiaProjectMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=sgmo_SBFiveTwoFiveMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_ProductOrServiceAxis=sgmo_OtherProductsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: